Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022
Authors' conclusion
Second, Medicare, which covers most patients receiving biologics nationally, had slow adoption rates even after the third biosimilar was introduced.
Study context
- Population
- All infliximab administrations (bio-originator or biosimilar) to patients aged ≥18 years, RISE registry (>1,100 US rheumatologists), April 2016 to September 2022
- Exposure
- Infliximab biosimilar uptake across Medicare, Medicaid and private insurers after successive biosimilar releases
- Outcome
- Biosimilar uptake after each infliximab biosimilar release (infliximab-dyyb, November 2016; infliximab-adba, July 2017; infliximab-axxq, July 2020)
Methodological detailsnational registry, electronic health records
- National registry
- Electronic health records
Main finding
As reported in the abstract
Average annual increase in biosimilar uptake, 2016 to June 2020 (first and second releases)
Observational data: associations, not effects.
Further findings
Average annual increase in biosimilar uptake after third release (July 2020)
Biosimilar uptake · September 2022
Original publication
Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022. Arthritis Rheumatol. Published 13 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →